PPMD Invests $400,000 in MyoGene Bio to Advance Gene Editing Research The Parent Project Muscular Dystrophy has secured $400,000 in funding for MyoGene Bio, significantly advancing research on Duchenne muscular dystrophy using gene editing technology.

PPMD Invests $400,000 in MyoGene Bio to Advance Gene Editing Research #USA #San_Diego #Duchenne_MD #MyoGene_Bio #PPMD_Venture

MyHealthTeam Unveils myMDteam, a Community for Muscular Dystrophy Patients MyHealthTeam has launched myMDteam, a dedicated online community for those with muscular dystrophy, focusing on support and information sharing among patients and caregivers.

MyHealthTeam Unveils myMDteam, a Community for Muscular Dystrophy Patients #United_States #San_Francisco #MyHealthTeam #Muscular_Dystrophy #Duchenne_MD

Avidity Biosciences Gains FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen Aiming at Duchenne Muscular Dystrophy Treatment Avidity Biosciences has been awarded Breakthrough Therapy designation by the FDA for delpacibart zotadirsen to treat Duchenne muscular dystrophy, enhancing treatment options for patients.

Avidity Biosciences Gains FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen Aiming at Duchenne Muscular Dystrophy Treatment #United_States #San_Diego #Avidity_Biosciences #Duchenne_MD #Delpacibart_Zotadirsen

Second Child's Death Raises Alarms Over Gene Therapy Approval Process by FDA The tragic deaths of two children linked to Elevidys, a gene therapy for Duchenne muscular dystrophy, highlight serious FDA oversight issues and calls for reform.

Second Child's Death Raises Alarms Over Gene Therapy Approval Process by FDA #United_States #Palm_Beach_Gardens #Sarepta_Therapeutics #ELEVIDYS #Duchenne_MD